Avelumab and Merkel Cell Carcinoma: Causation, FDA Warning, and Clinical Context

From General Health Awareness to Specific Drug Safety

For decades, public health communication has centered on general wellness principles and broad scientific literacy, equipping audiences with foundational knowledge about disease prevention and the importance of evidence-based medicine. This legacy framework has successfully normalized the idea that health outcomes are influenced by a complex interplay of lifestyle, environment, and medical interventions. Within this context, the role of pharmaceutical therapies has been presented as a carefully regulated pathway to improved outcomes, with safety monitoring systems designed to identify rare or delayed adverse events. As this general health perspective matures, it naturally extends to more specialized domains where therapeutic benefits must be weighed against specific risks. One such area involves the use of immunotherapeutic agents in oncology, where the balance between efficacy and safety is particularly nuanced. The transition from broad health awareness to focused occupational exposure concern occurs when we consider that healthcare professionals, patients, and caregivers may encounter these potent medications not only as recipients but also in handling, administration, or disposal contexts. This pivot requires acknowledging that the same rigorous scrutiny applied to general health information must now be directed toward understanding how exposure to a specific drug—such as an immune checkpoint inhibitor—might relate to subsequent health events. The shift is from abstract risk communication to concrete exposure scenarios, without venturing into mechanistic explanations or causal claims.

Avelumab: Mechanism, Approval, and Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is rising (https://pubmed.ncbi.nlm.nih.gov/35877101/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light exposure, leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Furthermore, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab. Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly evaluated ipilimumab plus nivolumab in avelumab-refractory MCC, confirming that immune checkpoint inhibition remains a viable strategy after progression on avelumab (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further supports the use of combination immunotherapy in this setting (https://pubmed.ncbi.nlm.nih.gov/35877101/).

FDA Warning and Causation Considerations

The mechanistic pathway linking avelumab to Merkel cell carcinoma is primarily therapeutic rather than causative. Avelumab is indicated for the treatment of MCC, and its use is associated with immune-related adverse events that can affect various organ systems. The FDA warning regarding avelumab and MCC likely pertains to the risk of immune-related adverse events, which are a known class effect of immune checkpoint inhibitors. These events can include severe or fatal immune-mediated reactions, such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. The adequacy of warnings regarding avelumab and MCC is supported by the drug's prescribing information, which includes detailed sections on immune-mediated adverse reactions and their management. However, the specific risk of developing MCC as a direct consequence of avelumab exposure is not supported by the available evidence; rather, avelumab is used to treat existing MCC. Causation-related considerations for affected patients focus on the timeline between avelumab exposure and documented harm. In the context of MCC treatment, harm is typically defined as disease progression or the development of immune-related adverse events. The JAVELIN Merkel 200 trial demonstrated that approximately one-third of patients achieved objective responses, indicating that a majority did not respond or experienced progression (https://pubmed.ncbi.nlm.nih.gov/29799096/). The timeline for response or progression is typically assessed at regular intervals during treatment, with imaging studies performed every 6 to 12 weeks. Immune-related adverse events can occur at any time during treatment, including after discontinuation, and their onset can range from days to months after the first dose. For patients who progress on avelumab, the median time to progression is not explicitly stated in the provided evidence, but the retrospective studies indicate that subsequent therapy with ipilimumab and nivolumab can be effective (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab is an established treatment for metastatic Merkel cell carcinoma, with a well-characterized efficacy and safety profile. The risk of immune-related adverse events is a significant consideration for patients, and the adequacy of warnings is reflected in the drug's labeling. Causation between avelumab and harm is primarily related to treatment failure or adverse events, rather than the induction of MCC. The timeline for these events is variable and requires close monitoring. For patients who become refractory to avelumab, alternative immune checkpoint inhibitor combinations offer a potential therapeutic option.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work?

Is there a causal link between avelumab and developing Merkel cell carcinoma?

No. Avelumab is used to treat existing Merkel cell carcinoma, not to cause it. The FDA warning pertains to immune-related adverse events, which are known side effects of immune checkpoint inhibitors. The available evidence does not support a causal link between avelumab exposure and the development of MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.